Maximum Atorvastatin Dose with Darolutamide
Atorvastatin can be used at standard doses up to 80 mg daily when combined with darolutamide, as there is no clinically significant drug-drug interaction between these two medications.
Key Drug Interaction Distinction
The critical point is that darolutamide interacts with rosuvastatin, not atorvastatin 1, 2. This distinction is essential for safe prescribing:
- Rosuvastatin is heavily dependent on BCRP (breast cancer resistance protein) and OATP (organic anion-transporting polypeptides) for clearance, which darolutamide inhibits 1
- Atorvastatin is primarily metabolized via CYP3A4 and does not rely significantly on BCRP/OATP transporters that darolutamide affects 2
- A case report documented rhabdomyolysis in a patient taking rosuvastatin 40 mg with darolutamide, where the maximum safe rosuvastatin dose should have been limited to 5 mg daily 1
Evidence from Clinical Trials
The ARAMIS phase III trial provides reassuring safety data:
- 1,509 patients with non-metastatic castration-resistant prostate cancer received darolutamide 600 mg twice daily 3, 2
- 34.5% of participants used lipid-modifying agents (including statins) concurrently 2
- Adverse event incidence was similar between statin users and non-users in both darolutamide and placebo arms 2
- Population pharmacokinetic analysis of 388 patients showed no significant effects of comedications (including statins) on darolutamide pharmacokinetics 2
Dosing Recommendations for Atorvastatin
Based on standard dyslipidemia guidelines applicable to this population:
- Standard dosing range: 10-80 mg daily can be used safely 4, 5, 4
- High-intensity therapy: Atorvastatin 40-80 mg is appropriate for patients requiring aggressive LDL reduction, such as those with established cardiovascular disease or diabetes 4, 6, 7, 4
- The PROVE IT trial demonstrated that atorvastatin 80 mg was well-tolerated with no cases of rhabdomyolysis, though liver enzyme elevations (>3x ULN) occurred in 3.3% of patients 6, 7
Monitoring Considerations
While no dose adjustment is needed, standard statin monitoring applies:
- Baseline and follow-up lipid panels at 4-12 weeks after initiation or dose changes 4
- Monitor for muscle symptoms (pain, tenderness, weakness) 1
- Check creatine kinase if unexplained muscle symptoms develop 1
- Liver function monitoring per standard statin guidelines 6, 7
Critical Safety Warning
Do not confuse atorvastatin with rosuvastatin when prescribing for patients on darolutamide:
- If rosuvastatin must be used with darolutamide, the maximum dose is 5 mg daily 1
- The patient in the case report was receiving rosuvastatin 40 mg (eight times the safe maximum) and developed rhabdomyolysis 1
- Consider switching patients from rosuvastatin to atorvastatin when initiating darolutamide to avoid this severe interaction 1